Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...

Mantle cell lymphoma (MCL) is a rare form of cancer that affects B cells. B cells are a type of white blood in your immune system. MCL is part of a larger group of cancers called ...

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

December 19, 2007 (Atlanta) — Results obtained with an intensive immunotherapy regimen in mantle-cell lymphoma are so good that they suggest that a cure is in sight, said Christian Geisler, MD ...

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an ...

The ECHO trial's international scope, spanning 27 countries, underscores the global effort to improve treatment for this aggressive form of non-Hodgkin lymphoma.

Calquence ® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma. News release. AstraZeneca. October 3, 2024.

Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and ...

SAN DIEGO — Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to randomized phase 3 data ...

Mantle cell lymphoma is a rare, aggressive type of non-Hodgkin lymphoma arising from malignant B cells in the mantle zone of lymph nodes. It accounts for about 5% of lymphoma cases, is more common ...